Business
Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025
NEW YORK, May 13, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new data from a matching-adjusted indirect comparison study evaluating taletrectinib versus entrectinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be presented in a poster session at ISPOR 2025, the Professional Society for Health Economics and Outcomes Research’s annual conference, taking place May 1
About this update from Nuvation Bio Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":864,"height":268,"url":"https://media.zenfs.com/en/business-wire.com/ccda0d35731f167fef23385d70fe8f4f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PfyILK67GXArU4rFRaw4CA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI5ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ccda0d35731f167fef23385d70fe8f4f","width":864,"height":268},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/mU8Vcpsm5pT0ZCiaYAfiAg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE3Mjg7aD01MzY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/ccda0d35731f167fef23385d70fe8f4f","width":864,"height":268}},"lazy":false},{"type":"text","content":"NEW YORK, May 13, 2025--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new data from a matching-adjusted indirect comparison study evaluating taletrectinib versus entrectinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be presented in a poster session at ISPOR 2025, the Professional Society for Health Economics and Outcomes Research’s annual conference, taking place May 13-16, 2025 in Montreal, QC, Canada.","length":552,"tagName":"p"},{"type":"text","content":"Presentation Overview:","length":22,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Title: Taletrectinib vs Entrectinib in ROS1-Positive (ROS1+) Non-Small Cell Lung Cancer (NSCLC): A Matching-Adjusted Indirect Comparison (MAIC)","length":143,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Presenter: Misako Nagasaka, M.D., Ph.D., Associate Professor – Division of Hematology and Oncology, UCI School of Medicine","length":122,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Date: Wednesday, May 14","length":23,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Session Time: 10:30 a.m. – 1:30 p.m. ET","length":39,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Session: Poster Session 1","length":25,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Presentation Number: CO151","length":26,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":378,"olType":false},{"type":"text","content":"The ma...